Thomas Schmidt Voss

Thomas Schmidt Voss

Auto-generated profile, based on publicly available information

Thomas Schmidt Voss

Steno Diabetes Center Aarhus Aarhus University Hospital Aarhus Denmark

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2019 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
AMAndreas Buch Møller
Andreas Buch Møller
SLSimon Lønbro
Simon Lønbro
JFJean Farup
Jean Farup
TVThomas Schmidt Voss
Thomas Schmidt Voss
NRNikolaj Rittig
Nikolaj Rittig
NJNiels Jessen
Niels Jessen

1 August 2017 in Cell Chemical Biology
Verified
Journal Article
Closed access
TSTrine Salomón
Trine Salomón
CSChristian Sibbersen
Christian Sibbersen
JHJakob Hansen
Jakob Hansen
DBDieter Britz
Dieter Britz
MSMads Vandsted Svart
Mads Vandsted Svart
MJMogens Johannsen
Mogens Johannsen

12 October 2016 in Diabetologia
Verified
Journal Article
Closed access
PDF file
TVThomas S. Voss
Thomas S. Voss
MVMikkel H. Vendelbo
Mikkel H. Vendelbo
UKUlla Kampmann
Ulla Kampmann
SPSteen Pedersen
Steen Pedersen
TNThomas S. Nielsen
Thomas S. Nielsen
NMNiels Møller
Niels Møller

13 September 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
NRNilani Ramshanker
Nilani Ramshanker
MAMaiken Aagaard
Maiken Aagaard
RHRikke Hjortebjerg
Rikke Hjortebjerg
TVThomas Schmidt Voss
Thomas Schmidt Voss
NMNiels Møller
Niels Møller
JFJan Frystyk
Jan Frystyk
Context Short-term glucocorticoid exposure increases serum IGF-I concentrations, but antagonizes IGF-I tissue signaling. The underlying mechanisms remain unknown. Objective To identify at which levels glucocorticoid inhibits IGF-I signaling. Design and methods Nineteen healthy males received prednisolone (37.5 mg daily) and placebo for 5 days in a randomized, double-blinded, placebo-controlled cross-over study. Serum was collected on day 1, 3 and 5, abdominal skin suction blister fluid (SBF; ≈interstitial fluid) on day 5 (n=9) together with muscle biopsies (n=19). The ability of serum and SBF to activate the IGF-I receptor (IGF-IR) (bioactive IGF) and its down-stream signaling proteins (IRS-1, Akt and mTOR) were assessed using IGF-IR transfected cells. Results Prednisolone increased IGF-I concentrations and bioactive IGF in serum (P≤0.001), but not in SBF, which when compared to serum contained less bioactive IGF (≈28%) after prednisolone (P<0.05). This observation was unexplained by SBF concentrations of IGFs and IGF-binding proteins (IGFBPs) -1 to -3. However, following prednisolone treatment, SBF contained less IGFBP-4 fragments (P<0.05) generated by pregnancy-associated plasma protein-A (PAPP-A). Concomitantly, prednisolone increased SBF levels of stanniocalcin-2 (STC2) (P=0.02) when compared to serum. STC2 blocks PAPP-A from cleaving IGFBP-4. Finally, prednisolone suppressed post-IGF-IR signaling pathways at the level of IRS-1(P<0.05), but did not change skeletal muscle IGF-IR, IGF-I or STC2 mRNA. Conclusion Prednisolone increased IGF-I concentrations and IGF bioactivity in serum, but not in tissue fluid. The latter may relate to a STC2-mediated inhibition of PAPP-A in tissue fluids. Furthermore, prednisolone induced post-IGF-IR resistance. Thus, glucocorticoid may exert distinct, compartment-specific effects on IGF-action.

1 April 2015 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
ELEsben S Lauritzen
Esben S Lauritzen
TVThomas Voss
Thomas Voss
UKUlla Kampmann
Ulla Kampmann
AMAnnette Mengel
Annette Mengel
MVMikkel H Vendelbo
Mikkel H Vendelbo
EVEsben Thyssen Vestergaard
Esben Thyssen Vestergaard
Objective: Ghrelin has glucoregulatory and orexigenic actions, but its role in acute hypoglycemia remains uncertain. We aimed to investigate circulating levels of acylghrelin (AG) and unacylated ghrelin (UAG) in response to hyperinsulinemia and to hypoglycemia.Design: A randomized, single-blind, placebo-controlled crossover study including 3 study days was performed at a university hospital clinical research center.Methods: Nine healthy men completed 3 study days: i) saline control (CTR), ii) hyperinsulinemic euglycemia (HE) (bolus insulin 0.1 IE/kg i.v. and glucose 20% i.v. for 105 min, plasma glucose ≈5 mmol/l), and iii) hyperinsulinemic hypoglycemia (HH) (bolus insulin 0.1 IE/kg i.v.).Results: HH and HE suppressed AG concentrations at t=45–60 min as compared with CTR (P<0.05). At t=90 min, a rebound increase in AG was observed in response to HH as compared with both HE and CTR (P<0.05). UAG also decreased during HH and HE at t=45 min (P<0.05), whereas the AG-to-UAG ratio remained unaffected.Conclusions: This study demonstrates that AG and UAG are directly suppressed by hyperinsulinemia and that AG concentrations increase after a latency of ≈1 h in response to hypoglycemia, suggesting a potential counterregulatory role of AG.